ArticleVaccines2023
Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.
Open access · goldAbstract read
In one paragraph
Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.Emerging microbes & infections · 2024Pooled it
- Monkeypox Virus (MPXV) Transmission Dynamics in Neighboring Countries as a Potential Threat to Kazakhstan.Viruses · 2026Review
- mRNA vaccines against monkeypox: bridging immunoinformatics, structural vaccinology, and translational advances toward pan-orthopox immunity.Folia microbiologica · 2026Review
- Persistent Immunity From Historic Smallpox Vaccination and Its Limited Cross-Neutralization of Monkeypox Virus: A Population-based Serological Study in Taiwan.Open forum infectious diseases · 2026Article
- Beyond counting the numbers - focused outbreaks response strategies are needed to control the mpox outbreak in Africa.One health outlook · 2026Article
- Insights into Monkeypox Virus: Host Immunity, Viral Immune Evasion, Recent Advances in Vaccines, Therapeutic Development, and Future Perspectives.Microorganisms · 2026Review
- Serological differentiation between Mpox infection and vaccine-induced immunity: a mini-review.Frontiers in immunology · 2026Review
- From neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Article
- An ultrasensitive and specific CRISPR-Cas13a-mediated point-of-care assay for monkeypox detection and PCR-based clade detection.Infectious diseases of poverty · 2025Article
- Early Diagnosis and Monitoring of Adaptive Immune Response in a Cohort of Mild Mpox Patients During the 2022 Wave.Microorganisms · 2025Article
- Modelling the potential spread of Clade Ib MPXV in Asian cities.BMJ public health · 2025Article
- Article
- Article
- Comparative Analysis of 2022 Outbreak MPXV and Previous Clade II MPXV.Journal of medical virology · 2024Article
- A Label-free Optical Biosensor-Based Point-of-Care Test for the Rapid Detection of Monkeypox Virus.medRxiv : the preprint server for health sciences · 2024Article
- An overview on mRNA-based vaccines to prevent monkeypox infection.Journal of nanobiotechnology · 2024Review
- Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.EClinicalMedicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 3 institutions in 2 countries.
Giulia MatusaliLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0002-2948-4243
Elisa PetruccioliTranslational Research Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Eleonora CiminiLaboratory of Cellular Immunology and Farmacology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0002-2659-0868
Francesca ColavitaLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0003-0640-8667
Aurora BettiniLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Eleonora TartagliaLaboratory of Cellular Immunology and Farmacology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Settimia SbarraTranslational Research Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Silvia MeschiLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0003-0924-993X
Daniele LapaLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Massimo FrancalanciaLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0003-3133-9237
Licia BordiLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Valentina MazzottaHIV/AIDS Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0002-0240-7504
Sabrina CoenLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Klizia MizzoniLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Alessia BeccaceceHighly Contagious Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Emanuele NicastriHighly Contagious Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0002-5606-8712
Luca PierelliUnità Operativa Complessa (UOC) Transfusion Medicine and Stem Cell, San Camillo Forlanini Hospital, 00152 Rome, Italy.
Andrea AntinoriHIV/AIDS Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0003-2121-4684
Enrico GirardiScientific Direction, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0001-8182-5896
Francesco VaiaGeneral Direction, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0001-7013-2250
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-2209-5966
Delia GolettiTranslational Research Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0001-8360-4376
Vincenzo PuroRisk Management Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0003-0291-4490
Fabrizio MaggiLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.ORCID 0000-0001-7489-5271
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITLa Jolla Institute for Immunology · USCarlo Forlanini Hospital · IT
Funding
Ministero della Salute Ricerca Corrente linea 1
Abstract
When the Mpox virus (MPXV) began spreading globally in 2022, it became critical to evaluate whether residual immunity from smallpox vaccination provided cross-protection. To assess the cross-immune response to MPXV, we collected serum samples (
Indexed as
adaptive immunityMpox virusneutralizing antibodiesOrthopoxvirussmallpox-vaccineT cell response
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.